Abstract-Angiopoietin-1 (Ang1) has powerful vascular protective effects: suppressing plasma leakage, inhibiting vascular inflammation, and preventing endothelial death. Preclinical studies indicate that Ang1 may be therapeutically useful in a number of situations, including treatment of edema, endotoxemia, and transplant arteriosclerosis. However, the ligand has also been implicated in vessel remodeling, induction of angiogenesis and pulmonary hypertension, indicating that strategies to minimize any deleterious effects while optimizing vessel protection are likely to be needed. This review surveys the published data on vascular protective effects of Ang1 and highlights the therapeutic potential of this ligand, as well as possible limitations to its use. We also consider the data on Ang1 receptors and speculate on how to maximize therapeutic benefit by targeting the Tie receptors.
A ngiopoietin-1 (Ang1) is an oligomeric-secreted glycoprotein and a member, with Ang2 and Ang3/4, of the angiopoietin family of growth factors. These ligands bind Tie2, one of two receptor tyrosine kinases, the other being Tie1, that make up the Tie family of receptors expressed primarily in vascular endothelium. The angiopoietin and Tie families have primary roles in the latter stages of vascular development and in adult vasculature, where they control remodeling and stabilization of vessels. Ang1 is required for correct organization and maturation of newly formed vessels and promotes quiescence and structural integrity of adult vasculature. The importance of Ang1 for developmental angiogenesis is illustrated in transgenic mice deficient in the ligand. These animals die at about embryonic day 12.5, and although the vasculature has formed, it displays decreased complexity with dilated vessels, diminished branching, and reduced numbers of small vessels. 1 In addition, blood vessels in the Ang1 Ϫ/Ϫ mice have fewer endothelial cells, defects in association of endothelia with extracellular matrix, and vessel rupture. 1 A key role for Tie2 in transducing these Ang1 signals is indicated by the phenotype of Tie2 Ϫ/Ϫ mice, which have many similarities with Ang1 Ϫ/Ϫ mice, including decreased sprouting, dilated vessels, lack of periendothelial support, and vessel rupture. [2] [3] [4] [5] A summary of the phenotypes of these and other Tie and angiopoietin transgenic mice is shown in Table 1 . The prostabilizing effects of Ang1 will be discussed later but are clearly demonstrated in studies in which Ang1 is directly administered or overexpressed leading to marked improvements in vascular integrity in both growing and adult mice.
Unusually for a group of ligands, the angiopoietin family has both agonist and antagonist members. Ang1 and Ang2 are best characterized in this respect and can have opposing effects on receptor activation, with Ang1 stimulating Tie2 and Ang2 capable of antagonizing this. 6 Consistent with these effects at the receptor level, genetic evidence indicates that Ang2 can counteract Ang1 activity. Ang2 overexpression in transgenic mice leads to embryonic death with a phenotype similar to Ang1 or Tie2 deletion. 6 Ang2 also disrupts endothelial monolayer interaction with smooth muscle cells in culture. 7 Thus, signaling through Tie2 appears to depend on the balance between Ang1 and Ang2. There is now strong evidence to support the concept that Ang1 provides a basal signal to promote and maintain quiescence and integrity of the endothelium in mature vessels, whereas Ang2 induced by hypoxia or other activators suppresses the effects of Ang1, resulting in vessel destabilization. The effects mediated by Ang2 thus allow vessel growth or regression depending on which other endothelial effectors are also present. 8 In recent studies, Ang1 has been shown to have potent effects on adult vessels including promotion of vessel survival, inhibition of vascular leakage, and suppression of inflammatory gene expression. Therefore, it is not surprising that this ligand is being assessed in preclinical studies and shows promise for therapeutic use in a range of pathologies including sepsis, stroke, transplant arteriosclerosis, and diabetic retinopathy. In addition to promoting vessel stability, Ang1 also stimulates vessel remodeling and angiogenesis and has been implicated in pulmonary hypertension (PH). These latter activities suggest therapeutic application may require strategies to minimize the possibility of potentially deleterious effects while optimizing vessel-protective effects. Being able to manipulate the effects of Ang1, directly or indirectly, for therapeutic benefit will require an understanding of the receptors and signaling pathways used by the ligand. Although Tie2 is the best established receptor for Ang1, there is emerging data showing the ligand may also signal through the related tyrosine kinase Tie1. 9 Furthermore, certain integrins such as ␣5␤1 have been found to bind Ang1 and may transduce some of its cellular effects. 10, 11 These preliminary data suggest that in addition to Tie2, two other receptors may participate in Ang1 signaling. Differences in signaling motifs and mechanisms between Tie2, Tie1, and integrins further suggest that the receptors may mediate distinct cellular actions of Ang1. This diversity could provide an opportunity to promote specific desired activities at the cellular or in vivo level by targeting particular Ang1 receptors.
Here we review the potential therapeutic importance and applications of Ang1 as well as possible limitations to its use that need to be addressed.
The Angiopoietin Family
The first member of the angiopoietin family to be discovered, Ang1, was identified by its ability to bind Tie2 extracellular domain. 12 Subsequently, low stringency screening was used to clone Ang2, 3, and 4. 6, 13 The best-characterized members of the family are Ang1 and Ang2, and these two ligands share Ϸ60% amino acid identity. 6 Ang1 and Ang2 bind to Tie2 with similar affinities; however, whereas Ang1 is an agonist, the ability of Ang2 to activate Tie2 appears to depend on the cell type and context. As indicated above, in endothelial cells, Ang2 is largely unable to activate Tie2, 6 although if the ligand is present at high concentrations or for prolonged periods, it can stimulate the receptor. 14, 15 In nonendothelial cells transfected to express Tie2, Ang2 acts as an agonist. 6 Mouse Ang3 and human Ang4 are orthologues and represent the third member of the Ang family. 13 Ang4 activates Tie2 in human endothelial cells, and Ang3 is an agonist for the receptor in mouse endothelium. 13, 16 The angiopoietins share a similar overall structure with a short amino-terminal motif followed by a coiled-coil domain and carboxy-terminal fibrinogen-like domain. 6, 12, 13 Binding of the ligands to Tie2 is mediated by their fibrinogen-like domains. 17 The precise residues required for Tie2 interaction have yet to be defined, although based on the crystal structure of the Ang2 fibrinogen domain and preliminary amino acid substitution analysis, a region in the carboxy-terminal half of the domain appears to be important. 18 The coiled-coil sequences of the angiopoietins are responsible for homooligomerization of the ligands. 17 Native Ang1 exists as trimeric, tetrameric, and pentameric homo-oligomers that cluster into multimeric structures via cysteines within the amino-terminal motif. 19, 20 This multimerization is essential for activation of Tie2 in endothelium, and Ang1 must present as a tetramer or higher-order structure to stimulate the receptor. 19, 20 Interestingly, Tie2 transfected into nonendothelial cells can be activated by dimeric Ang1, suggesting that in endothelial cells, coreceptors or regulators are present that require the ligand to assume higher-order multimers to be activating. 20 Native Ang2 exists as disulphide-linked homodimers, and recombinant Ang2 has been reported as trimeric, tetrameric, and pentameric oligomers. 20 In contrast to Ang1, there appears to be little multimerization of Ang2. 17, 19, 20 This incapacity to form higher-order multimers would prevent Ang2 from activating Tie2 and likely contributes to the ability of Ang2 to act as an antagonist. However, even multimeric constructs of the Ang2 fibrinogen domain are unable to activate endothelial Tie2, indicating that determinants in the receptor-binding domain of this ligand also prevent it from activating Tie2. 19, 20 Ang1 is widely expressed and is present in periendothelial cells in quiescent vasculature. 12, 21 In contrast, Ang2 expression occurs in areas of endothelial activation and angiogenesis, for example, in ovary and tumor vessel endothelia, where it coincides with vessel destabilization during angiogenesis. 6, 22 Ang2 expressed in endothelium is stored within Weibel-Palade bodies and is released rapidly after stimulation with thrombin and other agonists. 23 A broad range of factors has been reported to modulate Ang2 expression, including hypoxia, vascular endothelial growth factor (VEGF), angiotensin II, and leptin. 24 This pattern of expression and regulation of Ang1 and Ang2 is consistent with the concept that Ang1 provides a constitutive tonic signal to promote quiescence of the endothelium, and this is modified by the more actively regulated antagonist Ang2. 8 Much less is known about the expression patterns of Ang3/4. There are relatively few data on the sites of expression of Ang4. Endothelial cells are known to express the ligand, and it is upregulated by hypoxia and VEGF. 25, 26 Tissue distribution of Ang4 has not been studied in depth, although lung appears to express relatively high levels. 13
Ang1 Receptors Tie2
Ang1 binds and signals through the receptor tyrosine kinase Tie2. 12 This receptor and its close relative Tie1 share a similar overall structure with an extracellular domain comprising of an immunoglobulin (Ig)-like motif followed by three endothelial growth factor homology domains, a second Ig motif, and three fibronectin type III repeats. [27] [28] [29] The intracellular domains of Tie1 and Tie2 are tyrosine kinases with a short kinase insert region and carboxy-terminal tail. [27] [28] [29] Overall amino acid sequence identity between Tie1 and Tie2 intracellular domains is 76%. The primary sequences of Tie ectodomains are less conserved than intracellular portions of the receptors and have an amino acid identity of 31%. The region of Tie2 responsible for Ang1 binding is in the amino-terminal 360 amino acids of the receptor ectodomain, encompassing the first Ig motif and epidermal growth factor homology regions. 30
Tie1
Recent data indicate that in addition to the established receptor Tie2, Ang family members may signal through Tie1. Ang1 can induce Tie1 phosphorylation in endothelial cells, 9 but the mechanism for this activation still requires clarification. It is likely that either the ligand interacts with Tie1 to induce activation, or that it activates Tie1 indirectly via another Ang1 receptor. Activation of Tie1 indirectly would be consistent with the finding that Ang1 does not appear to bind recombinant soluble Tie1 extracellular domain. 12 However, it is also possible that the conformation of soluble ectodomain is different from the conformation of the fulllength Tie1 presented in a cellular context, or indeed that additional membrane components are required to enable cellular Tie1 to bind Ang1. Clearly, it will be important to define the mechanism by which Ang1 activates Tie1. Tie2 greatly enhances Ang1-activated Tie1 phosphorylation, probably via the interaction between the two receptors that has been reported previously. 9,31-33 Ang2 appears to antagonize the effects of Ang1 on Tie1 phosphorylation. 9 Thus, Ang2 could act to limit Ang1 signaling through Tie1 as it does with Tie2.
Integrins
In addition to Tie receptors, Ang1 as well as Ang2 has been found to bind integrins. Experiments with blocking antibodies, as well as cells deficient in certain integrins, suggest Ang1 can bind several different integrins, including ␣2␤1, ␣5␤1, ␣v␤3, and ␣v␤5. 10, 11, 34, 35 Ang1 has been shown to bind directly to ␣5␤1 34, 35 via the receptor binding fibrinogenlike domain of Ang1, 34 but the precise motif within this domain has not been defined. The interaction is inhibited by Arginine-Glycine-Aspartate (RGD) peptides; 10,11 however, the fibrinogen-like domain of Ang1 does not contain an RGD motif, or any known integrin binding site. 10 Nevertheless, it has been suggested that within this domain, a conserved Glutamine-Histidine-Arginine-Glutamate-Aspartate-GlycineSerine sequence, which is similar to integrin-binding sequences in fibrinogen and fibronectin, could mediate Ang binding. 10 Monomeric fibrinogen-like domains appear to bind ␣5␤1 and Tie2 with similar low affinity, 34 but the relative affinities of interaction of integrins and Tie2 with Ang1 in its natural multimerization state remain to be defined.
The possible signaling and cellular functions associated with Ang1 activation of Tie1 or integrins are discussed below. However, it is clear much work remains to be done to confirm and expand the data on Ang1 action through these receptors.
Cellular Effects and Signaling of Ang1 Apoptosis
The most extensively studied cellular effect of Ang1 is its ability to inhibit endothelial cell apoptosis. The ligand suppresses apoptosis in a variety of different endothelial cell types, including human umbilical vein endothelial cells (HUVECs), aortic and microvascular endothelial cells, and in response to stimuli ranging from serum deprivation, hyperosmolarity and tumor necrosis factor-␣ (TNF-␣) treatment to irradiation. 36 -41 Ang1 appears to inhibit apoptosis in some nonendothelial cells, including mouse cortical neurons 42 and skeletal and cardiac myocytes. 10 Tie2 is expressed in the neurons but not in the myocytes, leaving the receptor for Ang1 unknown in the latter.
The antiapoptotic effects of Ang1 involve the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, 21, 41 which is activated in response to Ang1 through recruitment of the regulatory p85 subunit of PI3K to phosphorylated tyrosine residue 1102 in the intracellular domain of Tie2. 43, 44 Stimulation of Akt via Ang1 activated PI3K results in phosphorylation and inhibition of the forkhead transcription factor FKHR in endothelial cells. 45 FKHR induces endothelial apoptosis and regulates expression of several genes in endothelium involved in vascular destabilization and remodeling, including Ang2. 45 This inhibitory effect of Ang1 on FKHR is consistent with its role in promoting vessel quiescence. In addition to cell survival, PI3K plays critical roles in a number of other cellular actions of Ang1, including modulation of gene expression, activation of endothelial migration, and suppression of inflammatory phenotype. The main signaling pathways known to be activated by Ang1 are summarized in the Figure. 
Migration
Ang1 stimulates endothelial cell migration, 46 -49 and this requires Tie2, as shown by experiments with endothelial cells from Tie2-deficient mice. 50 The signaling pathways by which Ang1 stimulates endothelial migration involve both PI3K and the adaptor protein Dok-R. After Tie2 activation, Dok-R is recruited to the receptor and becomes phosphorylated creating interaction sites for Nck and the serine kinase p21-activating kinase. 51 Recruitment of Dok-R to activated Tie2 is essential for Tie2-mediated migration. 51 This binding to Tie2 requires both phosphotyrosine binding (PTB) and pleckstrin homology domains of the adaptor, with the PTB domain interacting with phosphorylated Y 1108 on Tie2 and the pleckstrin homology domain being involved in PI3K-dependent membrane localization. 50 The adaptor protein ShcA is also recruited to Tie2 in endothelial cells after Ang1 stimulation and appears to have a role in migration and organization. 52 Increased endothelial motility in response to Ang1 also involves the GTPases RhoA and Rac1 as indicated by their activation in response to Ang1 and the ability of dominantnegative forms of the GTPases to suppress Ang1-induced endothelial motility. 48, 53 Outgrowth of neurons from rat dorsal root ganglia and migration of rat smooth muscle cells have also been found to be activated by Ang1, and both of these nonendothelial cell types express Tie2. 54 -56 Interestingly, Tie2-negative fibroblasts show increased movement in response to Ang1, suggesting that in these cells at least, the ligand can increase motility via receptors other than Tie2. 11
Reorganization
A cellular effect of Ang1 related to migration and reflecting the remodeling effects of Ang1 in vivo is the ability of the ligand to induce reorganization of cultured endothelial cells into tubule-like structures invading into 3D matrices. 49, 52, 57, 58 Ang1-stimulated reorganization of endothelial tubules and invasion into matrices is not seen in endothelial cells lacking Tie2 57 but can be stimulated by a Tie2-activating antibody in the rat aortic ring assay. 59 Consistent with such remodeling effects, Ang1 stimulates production of proteases, including plasmin and matrix metalloproteases, as well as suppressing secretion of tissue inhibitor of metalloproteases-2. 58 Use of inhibitors and dominant-negative constructs has indicated a number of signaling intermediates involved in Ang1-induced reorganization of endothelium and motility, including PI3K, the adaptor protein ShcA, focal adhesion kinase, and endothelial NO synthase. 49, 52, 58, 60 Thus, Ang1 activation of NO synthase has been reported in HUVECs and porcine coronary artery endothelial cells, 49, 60 and the ligand stimulates tyrosine phosphorylation of focal adhesion kinase in HUVECs. 58 Ang1 also stimulates extracellular signal-regulated kinase 1/2 (Erk1/2) in endothelial cells, 11, 45, 47, 61, 62 and this probably involves the upstream adaptor Grb2 that gets recruited to Y 1102 in activated Tie2. 44 The tyrosine phosphatase and adaptor protein Src homology-2-domain protein tyrosine phosphatase-2 is also recruited to activated Tie2 59, 63 and could also participate in Erk1/2 stimulation via its ability to recruit Grb2. 64 
Proliferation
Ang1 has been reported to have no, 46,47 mild, 15, 57 or significant 65 mitogenic activity in endothelial cells. Additional growth factors may be necessary for Ang1 to induce endothelial proliferation, and more work is required to define conclusively the conditions under which it may act to stimulate proliferation.
Inflammatory Gene Expression
Ang1 suppresses adhesion of leukocytes to VEGF-stimulated HUVECs 66 by inhibiting the expression of a number of inflammation-associated adhesion molecules. Specifically, E-selectin, intercellular adhesion molecule-1 (ICAM1), and vascular cell adhesion molecule-1 (VCAM1) expression is Ang1 signaling. Schematic representation of established and potential signaling pathways activated by Ang1 in endothelial cells. Key phosphotyrosines are shown for the carboxy-terminus of Tie2, and cellular functions regulated by Ang1 are indicated toward the bottom of the figure. The domain structure of Tie2 is very similar to the related Tie1 receptor tyrosine kinase. Tie2 is the well-established transducer of Ang1 signals, but recent data indicate that Tie1 is also activated by Ang1. Furthermore, heteromeric complexes between Tie1 and Tie2 were detected in cells expressing both receptors. However, possible signaling emanating from these heteromeric receptor complexes remains to be defined. Integrins have been found to interact with both Ang1 and Tie2, but the importance of these interactions on Tie2 signaling is largely unknown. Other details of the receptors, signaling intermediates, and functions are given in the text. The top left corner of the figure depicts the structural features of human Ang1 together with approximate amino acid residue number flanking each domain. After the secretory leader sequence (S) is the superclustering domain (SCD), coiled-coil domain (CCD), hinge region (H), and fibrinogen-related domain (FReD).
decreased by Ang1 in VEGF-activated HUVECs. 66, 67 Ang1 induces a transient small increase in P-selectin expression at the surface of HUVECs, with a corresponding increased neutrophil adhesion, within the first few minutes of treatment with Ang1. 68 In addition to effects on adhesion molecule expression, Ang1 blocks TNF-␣-and VEGF-induced tissue factor expression in HUVECs. 69 The signaling mechanism for these anti-inflammatory actions remains to be defined, although inhibitor and dominant-negative experiments show PI3K and Akt are required. 66, 69 In addition, Ang1 stimulation of endothelial cells promotes recruitment of A20 binding inhibitor of nuclear factor B-2 to Tie2, and this has been implicated in Ang1 suppression of nuclear factor B, 70 a transcription factor critical for regulation of inflammatory gene expression.
Endothelial Monolayer Integrity
An important cellular effect of Ang1 is its ability to improve integrity of endothelial monolayers. Permeability of monolayers of cultured HUVECs, human umbilical artery endothelial cells, and glomerular endothelial cells is suppressed by Ang1. 67, 71 The ligand augments integrity of unstimulated monolayers and counteracts the increased permeability after activation with thrombin, VEGF, or TNF-␣. 67, 71 Again, the signaling mechanisms mediating these effects have yet to be delineated. Tyrosine phosphorylation of vascular endothelial cadherin and platelet endothelial cell adhesion molecule-1 is decreased by Ang1 in endothelial cells. 67 The ligand also suppresses dissociation of vascular endothelial cadherin from ␤-catenin, and these effects could be involved in suppression of interendothelial leakage. 67, 72 Hematopoiesis Both Tie1 and Tie2 were cloned from leukemia cell lines. 27, 73 They are expressed in hematopoietic progenitor cells, 74, 75 and consistent with a role in hematopoiesis, the Tie2/Ang1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. 76 
Putative Signaling From Tie1 and Integrins
The majority of studies on cellular actions and signaling by Ang1 have focused on Tie2. With the recent findings that Ang1 may signal through Tie1 and possibly to some extent via integrins, it will be important to define the signaling pathways and cellular functions that these additional receptors regulate. Studies with Tie1 gene-targeted mice have shown that in vivo, Tie1 is required cell autonomously for endothelial cell survival during late embryogenesis. 3, 77 Thus, it is likely that Tie1 has a role in suppression of endothelial apoptosis, possibly via the PI3K pathway. Supporting this, it has been shown recently that the Tie1 intracellular domain can recruit the p85 subunit of PI3K and, using a chimeric receptor approach, that this is involved in Akt activation and suppression of UV-induced apoptosis in transfected fibroblasts. 78 The tyrosine in Tie1 involved in interaction with the p85 subunit of PI3K is present in the motif Y 1117 VNM. This motif is more similar to the preferred binding motif of p85 79 than the equivalent Y 1102 VNT sequence in Tie2, suggesting that activated Tie1 could be a more potent activator of PI3K than Tie2. Another important difference between signaling motifs in Tie2 and Tie1 is that a key tyrosine residue in Tie2 involved in regulating endothelial migration, Y 1108 , does not have an equivalent in Tie1, where phenylalanine replaces it. As discussed above, Y 1108 in Tie2 is responsible for recruiting Dok-R/Nck/p21-activating kinase, which is essential for Tie2-mediated endothelial migration. 50, 51 Therefore, it may be that although Tie1 could be a strong activator of PI3K and endothelial survival, it would not stimulate endothelial migration. Indeed, because PI3K has also been implicated in the anti-inflammatory activity of Ang1, it is an intriguing possibility that Tie1 could promote protective actions of endothelial survival and anti-inflammatory activities without promoting endothelial migration associated with vessel remodeling.
The idea that Ang1 signals through integrins is supported by the finding that in myocytes that lack Tie receptors, Ang1 activation of Akt and Erk1/2, as well as survival, is inhibited by RGD peptides and integrin-blocking antibodies. 10 Furthermore, a recent study found that the isolated Ang1 fibrinogen domain is able to bind ␣5␤1 and suppress permeability of an endothelial monolayer without stimulating Tie2. 34 Thus, integrins may signal from Ang1 independently of Tie2. However, the integrin ␣5␤1 also contributes to Tie2 signaling; it associates constitutively with Tie2 and increases the sensitivity of the receptor tyrosine kinase to Ang1, with the receptor and downstream substrate p85 becoming phosphorylated at lower concentrations of Ang1 when the integrin is engaged. 35 Ang1-activated endothelial motility is also enhanced in endothelial cells adhering to the ␣5␤1 ligand fibronectin. 35 The specific signaling pathways and downstream cellular and in vivo functions regulated by Ang1 need defining. The interactions between Tie2 and the putative new Ang1 receptors require investigation. Do any of the receptors act independently to mediate discrete actions of Ang1, or do they cooperate in overlapping functions? For example, there is strong evidence that Ang1 can act through Tie2 in cultured endothelial cells to inhibit apoptosis and stimulate migration, and activation of Tie2 does promote remodeling of endothelial tubes. However, the contribution of other Ang1 receptors to each of these cellular actions is yet to be defined. Furthermore, the involvement of Tie1 and integrins in the effects of the ligand on monolayer integrity or inflammatory gene expression require definition.
Vascular Protective Effects of Ang1 In Vivo
Some of the cellular effects of Ang1 suggest that the ligand would be vascular protective in vivo, and Table 2 summarizes the main cellular and in vivo effects of Ang1. Certainly, Ang1 has been found to promote blood vessel survival, inhibit vascular leakage, and suppress vessel inflammation.
Vessel Survival
Evidence for increased vessel survival in response to Ang1 in vivo is provided in studies of radiation-exposed mice, in which endothelial survival in microvessels of the intestinal villi is increased by the ligand. 80 The protective effects of Ang1 in this model differed between different vascular beds, with little protection afforded to liver microvessels but inhibition of apoptosis in lung and intestinal endothelial cells after intravenous administration of the ligand. The ligand also inhibits apoptosis of microvessel endothelium in rats treated with monocrotaline to induce pulmonary injury and hypertension. 81 
Permeability
Plasma leakage from skin vessels after treatment with inflammatory stimuli or VEGF is decreased by Ang1. 82, 83 This effect occurs with both acute and chronic Ang1 administration. VEGF-induced retinal vessel permeability is also decreased by Ang1, and the ligand reduces vascular leakage in the brain after experimental embolic cerebral occlusion in mice. 84, 85 
Inflammation
Ang1 has anti-inflammatory effects on the vasculature. This is seen in skin of mice transgenically overexpressing VEGF, in which leukocyte adhesion is decreased by coexpression of Ang1. 82 Decreased adhesion of leukocytes, as well as depressed expression of ICAM1, is also seen in retinal vessels of diabetic rats after Ang1 administration. 86 Similarly, expression of the leukocyte adhesion molecules E-selectin, ICAM1, and VCAM1 is suppressed by Ang1 in pulmonary vessels of lipopolysaccharide-treated mice. 87 Further evidence for in vivo anti-inflammatory effects of Ang1 is provided by the decrease in leukocyte infiltration and fibrosis seen in cardiac allografts of rats overexpressing the ligand. 88 Importantly, Ang2 has been shown recently to be a key regulator of vascular inflammation. 89 Ang2 appears to be required for TNF-␣-induced monocyte adhesion to cultured HUVECs and expression of ICAM1 and VCAM1. 89 Mice deficient in Ang2 have a markedly attenuated inflammatory response to Staphylococcus aureus, and other stimuli and administration of Ang2 reverses this. 89 These data are consistent with maintenance of endothelial quiescence via the anti-inflammatory actions of Ang1 and reversal of this by Ang2 antagonistic activity.
Remodeling
In addition to vessel protection, Ang1 has been implicated in vessel remodeling. In developing mice, treatment with Ang1 results in enlargement of vessels, particularly on the venous side of the microvasculature. 90 -92 Localized overexpression of Ang1 in the liver of developing mice induces vascular remodeling effects, including hepatic arterial sprouting and enlargement, as well as portal vein dilation. 91 The effects of Ang1 on vessel enlargement are more restricted in adult mice, with reports of moderate and reversible increases in vessel size in liver and enlargement of tracheal vessels. 90 -92 Stimulation of remodeling by Ang1 manifested by apparent angiogenesis has been reported in some studies. A potent Ang1 variant, COMP-Ang1, was found to stimulate angiogenesis in the mouse corneal micropocket assay. 93 Others have found Ang1 to be angiogenic in the presence of coactivators such as TNF-␣ or VEGF 40, 94 or even to suppress angiogenesis. 84, 95 Some of the variation in effects observed in these studies may be attributable to dissimilarities in potency and Ang1 administration route, along with possible differences in sensitivities between vascular beds.
Lymphatic Sprouting
As well as effects on blood vessels, Ang1 stimulates growth of lymphatics, with increased lymphangiogenesis and lymphatic sprouting and hyperplasia observed in mice in response to Ang1. 96, 97 
Pulmonary Hypertension
Ang1 has been implicated in PH, a disease in which pulmonary arterial pressure is increased and is associated with increased smooth muscle coverage of pulmonary arterioles. 98 However, the precise role of the ligand in PH pathogenesis is yet to be resolved. Increased expression of Ang1 at the mRNA and protein level has been reported in patients with PH, as well as increased levels of activated (phosphorylated) Tie2. 99 These changes have been associated with changes in expression of regulators of smooth muscle cell proliferation, specifically suppression of bone morphogenic protein receptor type 1A, and an increase expression of serotonin. 99, 100 It has been suggested that these events lead to elevated proliferation of smooth muscle cells around pulmonary arterioles resulting in the increased muscularization of the vessels. 99, 100 In support of a causative role for Ang1, transgenic overexpression of Ang1 in rat lung can result in a PH-like phenotype, and expression of soluble Tie2 ectodomain, to sequester Ang1, suppresses the pathology in monocrotaline-and Ang1-induced models of PH in rats. 100, 101 However, some anomalies in this model of PH pathogenesis need resolving. For example, it is not clear why Tie2 appears unactivated in Inhibits apoptosis 21,36 -41,47,115-117 Stimulates vessel survival, inhibits regression 80, 81, 90 Stimulates migration 11, 44, [47] [48] [49] 52 Stimulates remodeling [90] [91] [92] Stimulates tube formation/invasion 49, 52, 57, 58, 60, 118 Stimulates angiogenesis, alone or with VEGF/TNF-␣ 40, 60, 84, [93] [94] [95] Stimulates protease production 58 Stimulates lymphatic proliferation and sprouting in mice 96, 97 Stimulates proliferation 15, 65 Inhibits leukocyte adhesion 66, 67 Inhibits leukocyte adhesion and infiltration 82, 86, 88 Inhibits adhesion molecule expression 66, 67 Inhibits allograft fibrosis 88 Inhibits tissue factor expression 69 Inhibits endotoxemia 87 Inhibits nuclear factor-B 70 Promotes monolayer integrity 53, 67, 71, 72 Inhibits vascular leakage [82] [83] [84] [85] normal lung vessels when others have reported the receptor to be stimulated in quiescent lung vasculature. 102 Furthermore, Ang1 has not been reported previously to activate proliferation of smooth muscle cells surrounding vessels. In contrast to a causative role, Ang1 has also reported to protect against development of PH in the rat monocrotaline model. 81 In this case, it is hypothesized that endothelial apoptosis could lead to decreased vessel numbers in the pulmonary bed, causing increased resistance, and that Ang1 may protect against such endothelial loss. 81 Multiple factors contribute to development of PH in humans, 103 and additional work will be required to define the importance of Ang1 as well as the potential risks of elevating Ang1 in development of PH. In particular, the apparently contradictory findings of elevated Ang1 in PH and the protective effects of the ligand require further clarification. One possibility is that the reported increased Ang1 is a compensatory response rather than an initiating factor. 104
Potential Clinical Applications of Ang1
Clearly, the effects of Ang1 in vivo suggest that manipulation of this ligand could have therapeutic potential. Such manipulation could include direct administration of Ang1 or potent Ang1 mimetics as well as functionally increasing Ang1 by decreasing or blocking competitive antagonists such as Ang2. Microvascular regression contributes to a number of diseases, including diabetic retinopathy, allograft vasculopathy, and sepsis, 105 and the antiapoptotic effects of Ang1 would have possible therapeutic applications in counteracting such regression. Promotion of endothelial survival would also be beneficial in attempts to induce rapid vascularization of transplanted tissues and in limiting radiation damage associated with radiotherapy. Preclinical studies support the concept of therapeutic use of Ang1 to limit endothelial death. These include reports of the prosurvival effects of Ang1 on microvessels of the intestine in a radiation therapy mouse model, discussed above, 80 and increased survival of transplanted skin flaps in a rat model of reconstructive surgery. 106 Vascular leakage is problematic in inflammatory conditions, such as asthma, as well as diabetic retinopathy, stroke, and a variety of other pathologies. [107] [108] [109] The potential therapeutic use of Ang1 to limit edema is clearly indicated by its ability to inhibit VEGF-and inflammation-induced leakage from vessels of the skin in animal models. 82, 83 Ang1 suppression of VEGF-induced permeability of retinal vessels in mice provides a further preclinical demonstration of its therapeutic potential. 84 In a mouse model of stroke, Ang1 inhibited leakage from cerebral vessels and decreased lesion size. 85 In addition to decreasing vessel leakage, Ang1 could contribute to resolution of edema via its actions on lymphatic vessel growth. 97 The suppression of inflammatory gene expression in endothelial cells by Ang1 suggests that the ligand may be useful in suppressing vascular inflammation. This is supported by the preclinical studies that show inhibitory effects of Ang1 on leukocyte adhesion and extravasation in animal models of diabetic retinopathy, allograft arteriosclerosis, and sepsis. 86 -88 Ang1 has significant therapeutic potential. However, its actions to promote vessel remodeling, angiogenesis, and its possible involvement in PH could limit its usefulness. Ways to maximize the vascular protective effects of the ligand and minimize any potential for deleterious actions will need to be sought. A better understanding of the mechanisms of action of Ang1 will be required. This could then allow manipulation at the level of ligand, receptor(s), or intracellular signals to promote the desired therapeutic actions.
Conclusions
The effects of Ang1 on endothelial cells and blood vessels broadly fall into two categories: those associated with promotion of vessel protection, and those related to vessel remodeling and angiogenesis. Preclinical studies support possible therapeutic manipulation of Ang1 for promotion of vessel survival in transplanted tissue, suppression of vascular leakage in stroke, as well as protection from endotoxemia, diabetic retinopathy and allograft arteriosclerosis.
Ang1 mediates its effects through the Tie2 receptor tyrosine kinase. Recent results suggest that the situation may be more complex because it was shown that the related receptor Tie1 can be activated by Ang1 and thus may mediate Ang1-induced signaling. In addition, integrins appear to interact with both the ligand and the Tie2 receptor. Differences in signaling motifs between these three receptors, such as the possible lack of a Dok-R recruitment site in Tie1, suggest that they could have some distinct signaling and cellular activities. It will be important to define the specific functions of Ang1 that are mediated by each receptor in the cellular and in vivo context, the signaling pathways involved, as well as the significance of interactions and cross-talk between the receptors. It is certainly possible that a better understanding of Ang1 and its receptors will lead to identification of novel cellular, vascular, and possibly nonvascular activities controlled by Ang1 via these receptors. The different cellular and signaling effects of the Ang receptors could provide new opportunities for therapeutic manipulation of the vasculature. Thus, specific activation of one or a combination of Ang1 receptors, and associated signaling pathways, may promote optimum vessel protection while minimizing the possibility of inducing inappropriate vascular remodeling, for example. Correspondingly, other receptors or receptor combinations could be inhibited where it would be beneficial to induce vessel regression.
Irrespective of these possibilities, the unique vascular protective effects of Ang1 make this ligand very attractive for exploitation to provide novel therapeutic options applicable to a wide range of pathologies involving the vasculature.
